Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Vesalius Biocapital III is a European life sciences venture capital firm, established to manage investments in innovative healthcare solutions. The fund closed in May 2019 with €120 million in commitments, primarily from the European Investment Fund (EIF), which contributed €30 million. The firm is based in Strassen, Luxembourg, and focuses on later-stage companies that address unmet medical needs through strong intellectual property protection.
The firm targets investments in drug development, medical devices, diagnostics, and eHealth/mHealth sectors. Vesalius Biocapital III aims to support companies that have validated clinical or commercial traction, enhancing their growth potential and market reach. The fund typically invests between $1 million and $10 million per company, with a target portfolio of 10 to 15 companies.
Vesalius Biocapital has a team of seasoned professionals with extensive experience in the life sciences sector, corporate finance, and strategy consulting. Their expertise allows them to provide significant value to portfolio companies, helping them navigate clinical and commercial challenges.
Vesalius Biocapital III focuses on later-stage investments in European life science companies, specifically in the sectors of drug development, medical devices, diagnostics, and eHealth/mHealth. The fund's investment strategy emphasizes addressing unmet medical needs and supporting companies with strong intellectual property. This focus aligns with the growing demand for innovative healthcare solutions in Europe.
The firm typically invests in Series A, Series B, Series C, and Growth Equity stages, with check sizes ranging from $1 million to $10 million. Vesalius Biocapital III seeks companies that demonstrate validated clinical or commercial traction, ensuring that their investments are directed towards businesses with proven potential for success. The geographic focus is primarily on Europe, although there may be some exposure to the US market.
Vesalius Biocapital III has built a diverse portfolio of companies within the life sciences sector. Notable portfolio companies include:
These companies exemplify Vesalius Biocapital III's commitment to investing in innovative solutions that address significant healthcare challenges.
Guy Geldhof: CFO of Vesalius Biocapital Fund 1, Partner Fund 2, and Managing Partner Fund 3. He has extensive experience in finance and investment management within the life sciences sector.
Marc Lohrmann: Managing Partner of Vesalius Biocapital Fund 3, bringing a wealth of knowledge in venture capital and strategic investments.
Dr. Christian Schneider: Managing Partner across all three funds, with a strong background in life sciences and a focus on clinical development.
Stéphane Verdood: Managing Partner of Vesalius Biocapital Fund, contributing expertise in corporate finance and strategic consulting.
Gaston Matthyssens, PhD: Managing Partner with a focus on life sciences investments, leveraging his academic and industry experience to guide portfolio companies.
To pitch Vesalius Biocapital III, founders should utilize the investor portal at Vesalius Investor Portal or send an email to info@vesaliusbiocapital.com. It is essential to include a comprehensive deck that outlines the business model, market opportunity, and any clinical or commercial traction. Response times may vary, but founders should expect to hear back within a few weeks.
In May 2019, Vesalius Biocapital III announced the final close of its €120 million fund, which was a significant milestone for the firm. The fund has since been actively investing in notable companies within the life sciences sector, including Memo Therapeutics AG and SWORD Health.
Recent activity includes the firm's participation in Series B investments, showcasing their commitment to supporting innovative healthcare solutions. However, there have been no public announcements regarding new investments or exits in 2023, indicating a potential slowdown in activity.
What are Vesalius Biocapital III's investment criteria?
Vesalius Biocapital III invests in later-stage life science companies that focus on drug development, medical devices, diagnostics, and eHealth/mHealth. They prioritize companies that address unmet medical needs and possess strong intellectual property.
How can I apply or pitch to Vesalius Biocapital III?
Founders can pitch their startups through the Vesalius Biocapital investor portal at Vesalius Investor Portal or via email at info@vesaliusbiocapital.com. It is advisable to include a detailed business plan and information on clinical or commercial traction.
What makes Vesalius Biocapital III different from other investors?
The firm has a strong focus on the life sciences sector and leverages its team's deep technical and business expertise to support portfolio companies. Their emphasis on addressing unmet medical needs sets them apart in the venture capital landscape.
What is the geographic scope of Vesalius Biocapital III's investments?
Vesalius Biocapital III primarily invests in European companies, although they may have some exposure to the US market. Their focus on Europe aligns with their commitment to supporting local innovation in healthcare.
What is the typical check size for investments?
Vesalius Biocapital III typically invests between $1 million and $10 million in each portfolio company, depending on the specific needs and growth potential of the business.
How involved is Vesalius Biocapital III post-investment?
The firm actively supports its portfolio companies by providing guidance on clinical and commercial challenges, enhancing their growth potential and market reach. Their team’s expertise is a valuable resource for founders navigating the complexities of the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.